Yu, Jiali
Green, Michael D. http://orcid.org/0000-0003-4951-7118
Li, Shasha
Sun, Yilun http://orcid.org/0000-0002-1341-382X
Journey, Sara N. http://orcid.org/0000-0002-0987-9774
Choi, Jae Eun
Rizvi, Syed Monem
Qin, Angel
Waninger, Jessica J.
Lang, Xueting
Chopra, Zoey http://orcid.org/0000-0002-6349-2431
El Naqa, Issam http://orcid.org/0000-0001-6023-1132
Zhou, Jiajia
Bian, Yingjie http://orcid.org/0000-0002-9599-9907
Jiang, Long
Tezel, Alangoya
Skvarce, Jeremy
Achar, Rohan K.
Sitto, Merna
Rosen, Benjamin S.
Su, Fengyun
Narayanan, Sathiya P.
Cao, Xuhong
Wei, Shuang
Szeliga, Wojciech
Vatan, Linda
Mayo, Charles
Morgan, Meredith A.
Schonewolf, Caitlin A.
Cuneo, Kyle
Kryczek, Ilona http://orcid.org/0000-0002-3130-2533
Ma, Vincent T.
Lao, Christopher D.
Lawrence, Theodore S.
Ramnath, Nithya
Wen, Fei http://orcid.org/0000-0001-7970-4796
Chinnaiyan, Arul M. http://orcid.org/0000-0001-9282-3415
Cieslik, Marcin
Alva, Ajjai
Zou, Weiping http://orcid.org/0000-0001-7952-3549
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA248430, CA217648, CA123088, CA099985, CA193136, CA152470, CA233487, CA240515, S10OD020053, 1UM1HG006508, U01CA216440)
U-M | Comprehensive Cancer Center, University of Michigan (P30CA46592)
Article History
Received: 22 May 2020
Accepted: 13 October 2020
First Online: 4 January 2021
Competing interests
: J.Y., M.D.G., S.L., Y.S., S.N.J., J.E.C., S.M.R., J.J.W., X.L., Z.C., J.Z., Y.B., L.J., A.T., J.S., R.K.A., M.S., B.S.R., F.S., S.P.N., X.C., S.W., W.S., L.V., C.M., M.A.M., C.A.S., K.C., I.K., V.T.M., T.S.L., N.R., F.W., A.M.C. and M.C. report no conflicts. A.Q. has research funding from Merck and Clovis. I.E.N. serves as a consultant for Endectra. A.A. serves as a consultant for Merck, AstraZeneca, Bristol-Myers Squibb and Pfizer/EMD Serono. A.A. receives research funding through the University of Michigan from Merck, Genentech, Prometheus Laboratories, Mirati Therapeutics, Roche, Bayer, Progenics, Astellas Pharma, Arcus Biosciences, AstraZeneca, Bristol-Myers Squibb and Clovis Oncology. C.D.L. serves as a consultant for Immunocore. C.D.L receives travel, accommodations and expenses from Bristol-Myers Squibb and Immunocore. C.D.L. receives research funding from Bristol-Myers Squibb, Merck, Novartis and Dynavax. W.Z. has served as a scientific advisor for Cstone, Oncopia and Hengenix.